← Back to Search

Vaccine Education for Rheumatic Diseases

N/A
Recruiting
Led By Rosalind Ramsey-Goldman, MD, DrPH
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial tests whether training community leaders can help more Black adults with rheumatic conditions get the COVID-19 vaccine and boosters.

Who is the study for?
This trial is for Black individuals aged 18-85 with rheumatic diseases who want to help their community understand COVID-19 vaccines better. They must speak English, identify as Black/African American/African descent, and have a social network. Members of this network should be adults not fully vaccinated against COVID.Check my eligibility
What is being tested?
The study tests two types of training given to Popular Opinion Leaders (POLs) in the Black community on the benefits of COVID-19 vaccines and boosters. The goal is to see if these trainings can increase vaccine uptake and reduce hesitancy within their networks.See study design
What are the potential side effects?
Since this trial focuses on educational interventions rather than medical treatments, there are no direct side effects from medications or vaccines being studied here.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Receipt of >1 COVID-19 vaccine or booster dose
Secondary outcome measures
Change in COVID-19 vaccine hesitancy
Structure and composition of the Popular Opinion Leader outreach networks.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: COVID-19 vaccine and booster training with extra undisclosed componentExperimental Treatment1 Intervention
Group training involving COVID-19 vaccine and booster information, including background, development, and myths. Contains extra training component that is undisclosed until the end of the study so as not to introduce bias.
Group II: COVID-19 vaccine and booster trainingActive Control1 Intervention
Group training involving COVID-19 vaccine and booster information, including background, development, and myths.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,601 Previous Clinical Trials
915,599 Total Patients Enrolled
Brigham and Women's HospitalOTHER
1,624 Previous Clinical Trials
11,468,364 Total Patients Enrolled
Boston Children's HospitalOTHER
769 Previous Clinical Trials
5,580,469 Total Patients Enrolled

Media Library

COVID-19 vaccine and booster training with extra undisclosed component Clinical Trial Eligibility Overview. Trial Name: NCT05822219 — N/A
Coronavirus Vaccines Research Study Groups: COVID-19 vaccine and booster training with extra undisclosed component, COVID-19 vaccine and booster training
Coronavirus Vaccines Clinical Trial 2023: COVID-19 vaccine and booster training with extra undisclosed component Highlights & Side Effects. Trial Name: NCT05822219 — N/A
COVID-19 vaccine and booster training with extra undisclosed component 2023 Treatment Timeline for Medical Study. Trial Name: NCT05822219 — N/A
~40 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top